NOV03 eye drop effective in DED associated with MGD

NOV03 (perfluorohexyloctane) ophthalmic drop significantly reduced signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD) compared with hypotonic saline control, according to results of a randomized controlled trial.

In the study, 620 patients with a history of DED and signs of MGD were randomly assigned 1:1 to treatment with NOV03 (n = 311) or hypotonic saline (0.6%; n = 309) 4 times daily for 8 weeks.

The mean change in total corneal fluorescein staining and VAS dryness score from baseline to week 8 was statistically significantly greater for NOV03 compared with saline, with a statistically significant difference seen between groups as early as week 2.

Adverse events were similar between treatments; there were no serious adverse events or those leading to discontinuation of treatment.

Reference
Sheppard JD, Kurata F, Epitropoulos AT, et al; MOJAVE STUDY GROUP. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: the Randomized Phase 3 MOJAVE Study: NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction (69 characters; limit, 60). Am J Ophthalmol. 2023;S0002-9394(23)00098-3. doi: 10.1016/j.ajo.2023.03.008. Epub ahead of print. PMID: 36948372.